These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 4075858)

  • 1. Aztreonam: correlation between disk diffusion and agar plate dilutions susceptibility tests.
    Toma EC; Morisset R; Phaneuf D; Poisson M
    Chemotherapy; 1985; 31(6):451-5. PubMed ID: 4075858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefoperazone: regression analysis, disk content, and disk susceptibility testing considerations.
    Wright DN; Welch DF; Saxon BA; Clark SJ; Matsen JM
    Antimicrob Agents Chemother; 1982 Sep; 22(3):493-8. PubMed ID: 6215895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proposed disk diffusion susceptibility criteria for ofloxacin.
    Fuchs PC; Barry AL; Jones RN; Thornsberry C
    J Clin Microbiol; 1985 Aug; 22(2):310-1. PubMed ID: 3861612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of proposed criteria of disk susceptibility testing for tosufloxacin and lomefloxacin in NCCLS guidelines and WHO standards].
    Aihara M; Oguri T; Kanno H; Kubo S; Honda M; Satoh K; Daimon Y; Yamanaka K; Sugawara K; Furuta T
    Rinsho Byori; 1992 Jan; 40(1):73-80. PubMed ID: 1312183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro susceptibility to aztreonam.
    Lim VK
    Malays J Pathol; 1988 Aug; 10():61-4. PubMed ID: 3252078
    [No Abstract]   [Full Text] [Related]  

  • 6. Tentative inhibition zone criteria (Bauer-Kirby agar disk diffusion method) for rifampin against staphylococci.
    Traub WH; Spohr M; Bauer D
    Chemotherapy; 1987; 33(6):412-8. PubMed ID: 3428008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Aztreonam treatment of severe infections caused by gram-negative aerobic bacilli].
    Peter JD; Jehl F; Froehly S; Dupeyron JP; Monteil H; Rosset MA
    Pathol Biol (Paris); 1988 May; 36(5):525-30. PubMed ID: 3043352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro antimicrobial activity of carumonam (Ro 17-2301) and its influence on the activity of other antibiotics.
    Hoepelman IM; Steyger G; Rozenberg-Arska M; Verhoef J
    Chemotherapy; 1987; 33(2):103-9. PubMed ID: 3568798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility test of sitafloxacin against resistant gram-negative bacilli isolated from Thai patients by disk diffusion method.
    Thamlikitkul V; Tiengrim S
    J Med Assoc Thai; 2014 Mar; 97 Suppl 3():S7-12. PubMed ID: 24772575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of aztreonam against gram negative bacteria from clinical specimens and its comparison with other commonly used antibiotics.
    Qadri SM; Belobraydic KA
    Methods Find Exp Clin Pharmacol; 1986 Apr; 8(4):223-6. PubMed ID: 3088346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility testing of carumonam: interpretive criteria for 30-microgram disk tests and quality control guidelines for disk diffusion and broth microdilution methods.
    Jones RN; Barry AL
    J Clin Microbiol; 1987 Nov; 25(11):2243-6. PubMed ID: 3693552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility testing for Klebsiella pneumoniae isolates resistant to extended-spectrum beta-lactam antibiotics.
    Jan IS; Hsueh PR; Teng LJ; Ho SW; Luh KT
    J Formos Med Assoc; 1998 Oct; 97(10):661-6. PubMed ID: 9830274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of in vitro antimicrobial activity of cefazolin alone and in combination with cefmetazole or flomoxef using agar dilution method and disk diffusion method].
    Matsuo K; Uete T
    Jpn J Antibiot; 1992 Oct; 45(10):1253-66. PubMed ID: 1479676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing.
    Fuchs PC; Barry AL; Thornsberry C; Jones RN; Gavan TL; Gerlach EH; Sommers HM
    Antimicrob Agents Chemother; 1980 Jul; 18(1):88-93. PubMed ID: 6251750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Susceptibility of equine bacterial isolates to antimicrobial agents.
    Adamson PJ; Wilson WD; Hirsh DC; Baggot JD; Martin LD
    Am J Vet Res; 1985 Feb; 46(2):447-50. PubMed ID: 3994111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of antibiotic disk charge on concordance curve of cefotaxime ].
    Drugeon HB; Seon M; Reynaud A; Chung SS; Courtieu AL
    Pathol Biol (Paris); 1982 Jun; 30(6 Pt 2):517-21. PubMed ID: 6289229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefixime disk susceptibility test criteria.
    Fuchs PC; Barry AL; Jones RN
    J Clin Microbiol; 1986 Oct; 24(4):647-9. PubMed ID: 3771755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
    Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of aztreonam on the fecal aerobic flora in children].
    Borderon JC; Rastegar A; Ramponi N; Gold F; Laugier J
    Pathol Biol (Paris); 1987 May; 35(5):665-8. PubMed ID: 3112714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical laboratory approach for estimating effective administrative dose of cefoperazone. Evaluation of disc susceptibility test and its interpretation system].
    Matsuo K; Uete T
    Jpn J Antibiot; 1988 Oct; 41(10):1418-29. PubMed ID: 3204655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.